Eupraxia Pharmaceuticals reported a net loss of $14.5 million for the second quarter of 2026, compared with a loss of $8.7 million a year earlier, as research and development spending increased after the company doubled the size of Part 2 of its RESOLVE trial for EP-104GI in eosinophilic esophagitis, or EoE. As of June 30, 2026, the company held $52.4 million in cash and cash equivalents and $81.2 million in short-term investments, and said existing cash reserves are expected to fund operations into the second half of 2028. Eupraxia also highlighted Digestive Disease Week data showing improvement in inflammation and fibrosis after a single treatment of EP-104GI, including nine-month data from the highest-dose cohort in its Phase 1b/2a RESOLVE trial, where 66% of patients in Cohort 9 remained in clinical symptom remission at week 36. Management said interim data from the Phase 2b EoE trial are expected in Q4, followed by Phase 3 initiation and broader gastrointestinal indication expansion in 2027.